Tianjin TEDA Biomedical Engineering Co. Ltd. Class H (HK:8189)

:8189

8189

Tianjin TEDA Biomedical Engineering Co. Ltd. Class H

RESEARCH TOOLSreports

Tianjin TEDA Biomedical Engineering Co. Ltd. Class H (8189) Price & Analysis

2 Followers

8189 Stock Chart & Stats

HK$0.40

HK$0.00(0.00%)

At close: Jan 09 4:00 PM EST

HK$0.40

HK$0.00(0.00%)

Day’s Range― - ―

52-Week RangeHK$0.27 - HK$0.54

Previous CloseN/A

Volume305.00K

Average Volume (3M)1.41M

Market Cap

HK$618.98M

Enterprise ValueHK$599.75M

Total Cash (Recent Filing)HK$186.13M

Total Debt (Recent Filing)HK$112.58M

Price to Earnings (P/E)―

Beta0.20

Next Earnings

Aug 11, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.04

Shares Outstanding1,436,400,000

10 Day Avg. Volume824,500

30 Day Avg. Volume1,413,333

Financial Highlights & Ratios

PEG Ratio-0.19

Price to Book (P/B)24.48

Price to Sales (P/S)1.41

P/FCF Ratio-18.81

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Diverse Revenue StreamsThe company's diverse revenue streams, including medical devices, biopharmaceuticals, and partnerships, provide a robust foundation for long-term growth and resilience against market fluctuations.

Government ContractsGovernment contracts and funding enhance financial stability and market presence, providing a reliable revenue source and potential for expansion in the healthcare sector.

Commitment To InnovationA strong focus on innovation in medical technology positions the company to capitalize on industry advancements and improve patient outcomes, driving long-term competitive advantage.

Bears Say

High LeverageThe significant increase in leverage indicates a heavy reliance on debt financing, which poses financial risks and limits the company's flexibility in managing economic downturns.

Negative Cash FlowsPersistent negative cash flows highlight challenges in liquidity management and cash generation, potentially hindering the company's ability to invest in growth opportunities.

Declining RevenueThe declining revenue trend suggests weakening market position and demand for products, which could impact long-term profitability and necessitate strategic changes.

8189 FAQ

What was Tianjin TEDA Biomedical Engineering Co. Ltd. Class H’s price range in the past 12 months?

Tianjin TEDA Biomedical Engineering Co. Ltd. Class H lowest stock price was HK$0.27 and its highest was HK$0.54 in the past 12 months.

What is Tianjin TEDA Biomedical Engineering Co. Ltd. Class H’s market cap?

Tianjin TEDA Biomedical Engineering Co. Ltd. Class H’s market cap is HK$618.98M.

When is Tianjin TEDA Biomedical Engineering Co. Ltd. Class H’s upcoming earnings report date?

Tianjin TEDA Biomedical Engineering Co. Ltd. Class H’s upcoming earnings report date is Aug 11, 2026 which is in 124 days.

How were Tianjin TEDA Biomedical Engineering Co. Ltd. Class H’s earnings last quarter?

Tianjin TEDA Biomedical Engineering Co. Ltd. Class H released its earnings results on Mar 31, 2026. The company reported -HK$0.044 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.044.

Is Tianjin TEDA Biomedical Engineering Co. Ltd. Class H overvalued?

According to Wall Street analysts Tianjin TEDA Biomedical Engineering Co. Ltd. Class H’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Tianjin TEDA Biomedical Engineering Co. Ltd. Class H pay dividends?

Tianjin TEDA Biomedical Engineering Co. Ltd. Class H does not currently pay dividends.

What is Tianjin TEDA Biomedical Engineering Co. Ltd. Class H’s EPS estimate?

Tianjin TEDA Biomedical Engineering Co. Ltd. Class H’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Tianjin TEDA Biomedical Engineering Co. Ltd. Class H have?

Tianjin TEDA Biomedical Engineering Co. Ltd. Class H has 1,436,400,000 shares outstanding.

What happened to Tianjin TEDA Biomedical Engineering Co. Ltd. Class H’s price movement after its last earnings report?

Tianjin TEDA Biomedical Engineering Co. Ltd. Class H reported an EPS of -HK$0.044 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Tianjin TEDA Biomedical Engineering Co. Ltd. Class H?

Currently, no hedge funds are holding shares in HK:8189

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Tianjin TEDA Biomedical Engineering Co. Ltd. Class H Stock Smart Score

Underperform

Technicals

Fundamentals

Return on Equity

-8.95%

Trailing 12-Months

Asset Growth

-16.64%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Tianjin TEDA Biomedical Engineering Co. Ltd. Class H

Tianjin TEDA Biomedical Engineering Company Limited, together with its subsidiaries, engages in the research, development, manufacture, and sale of biological compound fertilizer products in the People's Republic of China. The company operates in two segments, Biological Compound Fertilizers Products, and Elderly Care and Health Care Services. Its biological compound fertilizer products include active fertilizer, mixture with nitrogen, phosphorus, and potassium with various formula that are used for the facilitation of balanced growth of grains, fruits, and vegetables. The company is also involved in the provision of integrated elderly and health care; and elderly equipment leasing services, as well as consulting, advisory, and assessment services. In addition, it provides and licenses electroencephalography photography (EEG) diagnosis detection services; and conducts EEG detection and diagnosis technology services. Further, the company engages in the research, development, manufacture, and application of biomedical science and technology projects; regional soil resources conditioning and remediation business; and provision of soil environmental quality standards research services. Tianjin TEDA Biomedical Engineering Company Limited was incorporated in 2000 and is headquartered in Tianjin, the People's Republic of China.